June 29, 2017
            Subaru Corporation Announces Production, Japan Sales and Export Results
for May 2017 (Flash Report)
            
            < May 2017 >
| May 2017 | Jan-May 2017 | |||||
| Units | 2017 vs 2016 | Units | ’17 vs ’16 | |||
| Domestic production *1 | 52,168  | -5.5% | 2nd consecutive month of y/y decrease | 288,958 | -3.5% | |
| Overseas production *2 | ☆ 34,117  | +87.7% | 12th consecutive month of y/y increase | 〇 168,498 | +58.0% | |
| Global production total | ☆ 86,285  | +17.6% | 10th consecutive month of y/y increase | 〇 457,456 | +12.7% | |
| Passenger vehicles | ☆ 10,839 | +31.5% | 5th consecutive month of y/y increase | 〇 64,770 | +21.4% | |
| Mini vehicles | 2,301 | +17.3% | First y/y increase in 2 months | 15,136 | +4.5% | |
| Japan sales total | 13,140 | +28.8% | 8th consecutive month of y/y increase | 79,906 | +17.8% | |
| Export total *3 | 39,647  | -4.5% | 4th consecutive month of y/y decrease | 217,237 | -8.9% | |
☆: Record high for the month of May
〇: Record high for January-May period
< Production >
| - | Domestic production decreased year-on-year, as production of the Impreza for North America was moved from Japan to the U.S. and the Levorg and WRX models were at their model change timing. | 
| - | Overseas production significantly increased year-on-year, due to increased production capacity as well as the all-new Impreza’s start of production in November 2016. | 
< Sales in Japan >
| - | Passenger vehicle sales increased year-on-year, led by strong demand for the all-new Impreza launched in October 2016 and the all-new Subaru XV launched in May this year. | 
| - | Mini vehicle sales increased year-on-year led by the all-new Chiffon which was launched in December 2016. | 
< Exports >
| - | Exports from Japan decreased year-on-year, as production of the Impreza for North America was moved from Japan to the U.S. and the Levorg and WRX models were at their model change timing. | 
*1 JAMA (Japan Automobile Manufacturers Association Inc.) report basis (CBU)
*2 Local line-off basis
*3 JAMA report basis
###
